Bevacizumab 400mg Injection

Bevacizumab 400mg Injection is a pioneering recombinant humanized monoclonal antibody that revolutionized oncology by targeting the tumor microenvironment rather than the cancer cell itself. It functions as an angiogenesis inhibitor, specifically binding to the Vascular Endothelial Growth Factor A (VEGF-A) protein. By neutralizing VEGF-A, the medication prevents it from interacting with receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells. This blockade effectively stops the formation of new blood vessels (angiogenesis) that tumors rely on to grow and metastasize, essentially “starving” the cancer of oxygen and nutrients. Furthermore, Bevacizumab normalizes the remaining tumor vasculature, which can improve the delivery of concomitant chemotherapy drugs into the tumor core. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for inhibiting metastatic spread, serving as a versatile backbone biological therapy across multiple tumor types.

The 400mg/16ml vial is the high-volume dosing unit designed to facilitate the preparation of standard adult infusions. Since dosing is weight-based (typically ranging from 5 mg/kg to 15 mg/kg), a single infusion for an average adult often requires doses between 400mg and 1000mg. The 400mg vial serves as the primary building block for these larger doses, significantly reducing the number of vials needed per patient compared to the smaller 100mg unit. This efficiency streamlines pharmacy workflow, reduces the risk of contamination during compounding, and optimizes inventory management for high-volume oncology centers.

Indications / Uses of Bevacizumab 400mg Injection

Bevacizumab 400mg Injection is commonly prescribed for the specialized management of the following advanced malignancies:

• Metastatic Colorectal Cancer (mCRC): It is indicated as a first- or second-line treatment in combination with fluorouracil-based chemotherapy (e.g., FOLFOX or FOLFIRI).
• Non-Squamous Non-Small Cell Lung Cancer (NSCLC): The medication is used in combination with carboplatin and paclitaxel for the first-line treatment of patients with unresectable, locally advanced, recurrent, or metastatic non-squamous NSCLC.
• Glioblastoma (GBM): It is indicated for the treatment of recurrent glioblastoma in adults.
• Metastatic Renal Cell Carcinoma (mRCC): It is used in combination with interferon alfa for the treatment of metastatic kidney cancer.
• Cervical & Ovarian Cancers: It is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer and for platinum-resistant or platinum-sensitive recurrent epithelial ovarian cancer.

Key Features

• VEGF Neutralization: The primary feature of Bevacizumab 400mg Injection is its specific binding to the VEGF ligand, preventing the “growth signal” from reaching blood vessels.
• High-Volume Efficiency: The 400mg vial size is optimized for adult dosing, minimizing the number of vials required for compounding high-dose infusions.
• Tumor Starvation: It halts the development of the neovasculature required for tumor expansion beyond 2mm in size.
• Chemosensitization: By normalizing leaky tumor blood vessels, it enhances the delivery and efficacy of chemotherapy agents.
• Broad Efficacy: It is one of the most versatile biologics, approved for use in cancers of the colon, lung, kidney, brain, and female reproductive tract.

Storage for Bevacizumab 400mg Injection

To preserve the structural integrity and biological activity of the monoclonal antibody, Bevacizumab 400mg Injection must be stored under refrigeration, typically between 2°C and 8°C (36°F to 46°F). Do not freeze and do not shake the vial, as mechanical stress can denature the protein. The vial should be kept in its original carton to protect it from light until the time of use. Once diluted for infusion, the solution should be used immediately or stored under refrigeration for no more than 24 hours. Store the medication in a secure, professional medical refrigerator strictly out of the reach of children.

Important Note on Bevacizumab 400mg Injection

The administration of Bevacizumab 400mg Injection is associated with serious, sometimes fatal, toxicities. Gastrointestinal (GI) Perforation (a hole in the stomach or intestine) is a rare but life-threatening risk; patients reporting severe abdominal pain must be evaluated immediately.

Wound Healing Complications: Bevacizumab impairs the body’s ability to heal wounds. It must not be initiated for at least 28 days following major surgery and should be suspended prior to elective surgery. The surgical incision must be fully healed before starting therapy.

Severe Hemorrhage: Severe or fatal bleeding (e.g., hemoptysis in lung cancer patients) can occur. It should not be used in patients with a history of coughing up blood. Hypertension (high blood pressure) and Proteinuria (protein in urine) are common side effects requiring regular monitoring. Bevacizumab 400mg Injection can cause fetal harm (Pregnancy Category D); effective contraception is mandatory. By strictly following these professional guidelines and surgical hold protocols, healthcare providers can safely maximize the survival benefits of Bevacizumab 400mg Injection.